Guillain-Barré syndrome natural history, complications, and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 17: Line 17:
==Prognosis==
==Prognosis==
* [[Recovery]] can take weeks or years.
* [[Recovery]] can take weeks or years.
* Most people survive and recover completely.
* Approximately 80% of patients have a complete recovery within a few months to a year, although minor findings may persist, such as [[areflexia]].
* About 5–10% recover with severe disability, with most of such cases involving severe proximal motor and sensory axonal damage with inability of axonal regeneration.
* A patient's outcome is most likely to be very good when the symptoms go away within 3 weeks after they first started.
* A patient's outcome is most likely to be very good when the symptoms go away within 3 weeks after they first started.
* According to the National Institute of Neurological Disorders and Stroke, about 30% of patients still have some [[weakness]] after 3 years. Mild [[weakness]] may persist for some people.
* According to the National Institute of Neurological Disorders and Stroke, about 30% of patients still have some [[weakness]] after 3 years. Mild [[weakness]] may persist for some people.
* Despite all improvements in treatment and supportive care, the death rate is still about 2–3% even in the best intensive care units.
* Worldwide, the death rate runs slightly higher (4%), mostly from a lack of availability of life support equipment during the lengthy plateau lasting four to six weeks, and in some cases up to one year, when a ventilator is needed in the worst cases.
* About 5–10% of patients have one or more late relapses, in which case they are then classified as having [[chronic inflammatory demyelinating polyneuropathy]] (CIDP).
* Poor prognostic factors include age over 40 years, history of preceding diarrheal illness, requiring ventilator support, high anti-GM1 [[titre]], and poor upper limb muscle strength.


==Possible complications==
==Possible complications==

Revision as of 03:05, 27 February 2012

Guillain-Barré syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Guillain-Barré syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Guillain-Barré syndrome natural history, complications, and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Guillain-Barré syndrome natural history, complications, and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Guillain-Barré syndrome natural history, complications, and prognosis

CDC on Guillain-Barré syndrome natural history, complications, and prognosis

Guillain-Barré syndrome natural history, complications, and prognosis in the news

Blogs on Guillain-Barré syndrome natural history, complications, and prognosis

Directions to Hospitals Treating Guillain-Barré syndrome

Risk calculators and risk factors for Guillain-Barré syndrome natural history, complications, and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Priyamvada Singh, MBBS [2]

Overview

Guillain-Barré syndrome (GBS) is an acute, autoimmune, polyradiculoneuropathy affecting the peripheral nervous system, usually triggered by an acute infectious process. Approximately 80% of patients have a complete recovery within a few months to a year, although minor findings may persist. A patient's outcome is most likely to be very good when the symptoms go away within 3 weeks after they first started. Complications like paralysis, respiratory failure and hypotension can be seen in these patients.

Natural history

  • Most of the time recovery starts after 4th week from the onset of the disease.
  • Approximately 80% of patients have a complete recovery within a few months to a year, although minor findings may persist, such as areflexia.
  • About 5-10% recover with severe disability, with most of such cases involving severe proximal motor and sensory axonal damage with inability of axonal regeneration.
  • However, this is a grave disease and despite all improvements in treatment and supportive care, the death rate among patients with this disease is still about 2-3% even in the best intensive care units.
  • Worldwide, the death rate runs slightly higher (4%), mostly from a lack of availability of life support equipment during the lengthy plateau lasting 4 to 6 weeks, and in some cases up to 1 year, when a ventilator is needed in the worse cases.
  • About 5-10% of patients have one or more late relapses, in which case they are then classified as having chronic inflammatory demyelinating polyneuropathy (CIDP).

Prognosis

  • Recovery can take weeks or years.
  • Approximately 80% of patients have a complete recovery within a few months to a year, although minor findings may persist, such as areflexia.
  • About 5–10% recover with severe disability, with most of such cases involving severe proximal motor and sensory axonal damage with inability of axonal regeneration.
  • A patient's outcome is most likely to be very good when the symptoms go away within 3 weeks after they first started.
  • According to the National Institute of Neurological Disorders and Stroke, about 30% of patients still have some weakness after 3 years. Mild weakness may persist for some people.
  • Despite all improvements in treatment and supportive care, the death rate is still about 2–3% even in the best intensive care units.
  • Worldwide, the death rate runs slightly higher (4%), mostly from a lack of availability of life support equipment during the lengthy plateau lasting four to six weeks, and in some cases up to one year, when a ventilator is needed in the worst cases.
  • About 5–10% of patients have one or more late relapses, in which case they are then classified as having chronic inflammatory demyelinating polyneuropathy (CIDP).
  • Poor prognostic factors include age over 40 years, history of preceding diarrheal illness, requiring ventilator support, high anti-GM1 titre, and poor upper limb muscle strength.

Possible complications

Complications related to disease

Complications caused due to immobility

References

Template:WH Template:WS